Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 3 papers. Top paper: “Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576”.
Paula A. Lengerke-Diaz, Juliana Vélez Luján, Michael Y. Choi, Eider Moreno-Cortes, José Vicente Forero-Forero +7 more
Hiren Karathia, Deepak Kumar, Roberto Vera Alvarez, Paula A. Lengerke-Diaz, José Vicente Forero-Forero +15 more
Hiren Karathia, Deepak Kumar, Roberto Vera Alvarez, Jose Vicente Forero-Forero, Eider Moreno +15 more